Biomarkers in Coronary Artery Bypass Surgery: ready for prime time and outcome prediction?

Frontiers in Cardiovascular Medicine

卷:2

Giorgia eBonalumi¹  Paolo ePoggio¹  Veronika eMyasoedova¹  Alessandro eParolari²  Paola eSongia³  Elena eTremoli³  Alberto ePilozzi³  Francesco eAlamanni³  Davide ePacini⁴ 

[1] Centro Cardiologico Monzino IRCCS;

[2] Policlinico San Donato IRCCS;

[3] Università degli Studi di Milano;

[4] Università di Bologna - S.Orsola-Malpighi;

关键词: Biomarkers, Pharmacological;    Coronary Artery Bypass;    Genetic Markers;    outcome prediction;    Dynamic markers;   

DOI  :  10.3389/fcvm.2015.00039

来源: DOAJ

【 摘 要 】

Coronary artery bypass surgery (CABG) is still one of the most frequently performed surgical procedures all over the world. The results of this procedure have been constantly improved over the years with low perioperative mortality rates, and with relatively low complication rates. To further improve these outstanding results the clinicians focused their attention at biomarkers as outcome predictors. Although biological testing for disease prediction has already been discussed many times, the role of biomarkers in outcome prediction after CABG is still controversial. In this paper we reviewed the current knowledge regarding the role of genetic and dynamic biomarkers and their possible association with the occurrence of adverse clinical outcomes after CABG. We also took into consideration the molecular pathway activation and the possible imbalance that may affect hard outcomes and graft patency. We analysed biomarkers classified in two different categories depending on their possibility to change over time: genetic markers and dynamic markers. Moreover, we evaluated these markers by dividing them, into sub-categories, such as inflammation, haemostasis, renin-angiotensin, endothelial function and other pathways.We showed that biomarkers might be associated with unfavourable outcomes after surgery, and in some cases improved outcome prediction. However, the identification of a specific panel of biomarkers or of some algorithms including biomarkers is still in an early developmental phase. Finally, larger studies are needed to analyse broad panel of biomarkers with the specific aim to evaluate the prediction of hard outcomes and graft patency.

【 授权许可】

Unknown